



Vanadium in Biosphere and Its Role in Biological Processes

Deepika Tripathi¹ · Veena Mani¹ · Ravi Prakash Pal¹

Received: 9 July 2017 / Accepted: 26 February 2018
© Springer Science+Business Media, LLC, part of Springer Nature 2018

Abstract

Ultra-trace elements or occasionally beneficial elements (OBE) are the new categories of minerals including vanadium (V). The importance of V is attributed due to its multifaceted biological roles, i.e., glucose and lipid metabolism as an insulin-mimetic, antilipemic and a potent stress alleviating agent in diabetes when vanadium is administered at lower doses. It competes with iron for transferrin (binding site for transportation) and with lactoferrin as it is secreted in milk also. The intracellular enzyme protein tyrosine phosphatase, causing the dephosphorylation at beta subunit of the insulin receptor, is inhibited by vanadium, thus facilitating the uptake of glucose inside the cell but only in the presence of insulin. Vanadium could be useful as a potential immune-stimulating agent and also as an antiinflammatory therapeutic metallodrug targeting various diseases. Physiological state and dose of vanadium compounds hold importance in causing toxicity also. Research has been carried out mostly on laboratory animals but evidence for vanadium importance as a therapeutic agent are available in humans and large animals also. This review examines the potential biochemical and molecular role, possible kinetics and distribution, essentiality, immunity, and toxicity-related study of vanadium in a biological system.

Keywords Metabolic role · Insulin-mimetic · Biological function · Vanadium

Introduction

Minerals are inorganic elements, without carbon, found in small amounts in all body tissues and fluids. Although they yield no energy, minerals play an important role in many activities in the body [1, 2]. The importance of mineral elements in human, animal, and plant nutrition has been well recognized as they could be essential nutrients required for metabolic functions such as growth and development, immunity, and reproduction in both human and animals. Essential elements are ubiquitous in the environment, and its dietary deficiency results in a suboptimal biological function which is preventable or reversible by physiological amounts of the element. Minerals may be broadly classified as macro (major) or micro (trace) elements. The macro- and microminerals are required in amounts greater than and less than 100 mg/g [3], respectively. In addition to major and trace elements, small amounts of heavier elements are also present in the biological systems which are categorized as “ultra-trace” or “possibly

essential elements” which include aluminum (Al), arsenic (As), cobalt (Co), chromium (Cr), fluorine (F), molybdenum (Mo), nickel (Ni), silicon (Si), tin (Sn), and vanadium (V) [4]. An ultra-trace element is one that normally comprises less than 1 µg/g of a given organism but still plays a significant role in its metabolism. These are required with estimated dietary requirements usually less than 1 mg/kg and often less than 50 µg/kg diet in laboratory animals [5]. Vanadium is believed to be important for normal cell function and development [6]. It acts as a cofactor for enhancing or inhibiting the enzymatic activity. It exists in all tissues involved in glucose homeostasis, lipid metabolism, antioxidant functions, and as an immunomodulator which has to be established in human and animals.

Physicochemical Properties

Vanadium was discovered by [Andres Manuel del Rio](#) in 1801 in [Mexico](#). It is classified as a transition element belonging to Group VB of the periodic table with atomic number 23, molecular weight 50.94, melting point 1890 °C, and a boiling point of 3380 °C, being the 22nd discovered element in the earth crust [7, 8] which never occurs unbound in nature. Vanadium compounds in general fall into three major categories, including inorganic vanadium salts (vanadate and vanadyl), peroxovanadium complexes, and organic V

✉ Deepika Tripathi
deepika.trip03@gmail.com

¹ National Dairy Research Institute, Karnal, Haryana, India

compounds. The average content of V is similar to that of zinc [9] constituting about 0.015% of earth's crust. The relevant forms are vanadyl sulfate, sodium metavanadate, sodium orthovanadate, and vanadium pentoxide [10]. It can exist in a variety of oxidation states $-1, 0, +2, +3, +4,$ and $+5$; the $+5$ oxidation state latter being predominant under physiological conditions. The $+5$ oxidation state of V exists as anionic metavanadate (VO^{-3}) or orthovanadate (H_2VO^{-4}) resembling phosphates, whereas $+4$ oxidation states exist as cationic vanadyl which resembles magnesium (Mg^{2+}) [11]. The pentavalent (VO^{3-}) form predominates in extracellular body fluids, whereas the quadrivalent (VO^{+2}) is most common intracellularly [12].

Occurrence

Soil

Vanadium is ubiquitously distributed in the environment. Naturally occurring compounds which contains V are carnottite, davidite, vanadinite, roscoelite, patronite, and bravoite [8, 13]. It is concentrated mainly in mafic rocks such as basalt, gabbro (200–250 mg V/kg), shales (100–130 mg/kg), and rock phosphate, a major source of phosphorus in animal diets [14]. Wheat, rye, and red clover are indicator plants for V concentration in soil. *Cichorium intybus*, *Eupatorium capillifolium*, *Astragalus ssp.*, *Allium macropetalum*, *Castilleja angustifolia*, and *Chrysothamnus viscidiflorus* also indicate V levels in soil [15, 16].

Plants

Plants passively take up certain minerals from the soils that are not essential for their growth and development, but affects plants either favorably as nutrients or unfavorably as toxins. Among these are Na, I, Co, Se, Cr, Sn, F, and V that might be required by animals, but not by the plants on which they are fed. Since crops are not usually supplied with these elements, it is possible that through intensive agricultural practices, these may get depleted in the soil, thus becoming unavailable in required amounts to the animals that are fed on such plants. A lower concentration of V in soils is beneficial for plant growth and < 2 mg/kg V enhanced chlorophyll synthesis and nitrogen fixation and also facilitates utilization of potassium from the soil by the plants [17]. In another study, it was reported that < 30 mg/kg V in soil enhanced the growth of soybean but at a higher level, the shoot and roots biomass were decreased [18]. Plants are known as major V flux from soil to organisms [19] due to direct exposure, uptake, and accumulation of V in them. Vanadium concentrations in plant species vary with their leaf-stalk ratio; leaves contain higher V content than seeds and fruits [20]. It is present in vanadyl form in feeds

with concentrations of less than 1 ng V/g [21]. In other natural foodstuffs also, it is present mostly in vanadyl (VO^{2+}) form [22]. Whole grains, seafood, meats, and dairy products generally contain 5–30 ng/g of V [23], whereas 10 μg V/kg DM [20] is present in cow's milk. Black pepper, mushroom, parsley, dill seed, cereals, fruits, and shellfish are some of the main sources of V with concentration ranging from 0.05 to 2 mg/kg [24]. Mushrooms accumulate 400 times more V than other plants [25, 26].

Water

Concentration of V in water varies with the geographical location and ranges from 0.2 to > 100 $\mu\text{g}/\text{L}$ in freshwater and from 0.2 to 29 $\mu\text{g}/\text{L}$ in seawater [27]. According to the report of WHO [28], it is present in seawater in range of 1 to 3 $\mu\text{g}/\text{L}$ and in sediments from 20 to 200 $\mu\text{g}/\text{g}$. The US Department of Energy [29] documented that the accepted safe limit for V in drinking water is 0.33 mg/L. Although, WHO [30] has recommended a level of 10 μg V/L in drinking water (ranging from 1 to 30 $\mu\text{g}/\text{L}$), with an average of 5 μg V/L.

Possible Role of Vanadium in Animals and Humans

Vanadium is a transition metal which is an endogenous constituent of most mammalian tissues. The low dose of V at cellular and subcellular levels has a potential beneficial effect [31]. Although the essentiality of V is still not clear in humans and animals, in a lower concentration, it is necessary for microorganisms, plants, and animals and its deficiency in living organisms is associated with numerous side-effects [32, 33]. V maintains plasma glucose levels by reducing its level of type 1 and type 2 diabetes mellitus lacking insulin sensitivity [34]. Also, it is reported that V alleviates cholesterol levels, heart disease, syphilis, tuberculosis, anemia, and edema, prevents cancer [34–36], and is needed for iodine metabolism and thyroid function. V salts facilitate the calcium deposition in the bones and are required for the formation of the musculoskeletal system [37] as its deficiency results into reduced growth, poor development of bone and teeth, and impaired reproductive capacity [38]. Like vanadate, decavanadate ion also interacts with major proteins such as myosin, actin, and Ca^{2+} -ATPase, thereby affecting mitochondrial functions besides inducing changes in several cellular antioxidant markers [39]. Decavanadate increased the SOD enzyme activity, whereas no changes were reported for vanadate, but this effect largely depends on the mode of administration of decavanadate. In human beings, pharmacologic amounts of V (i.e., 10 to 100 times normal intake) affect cholesterol and triglyceride metabolism and influence the shape of erythrocytes. Besides this, it stimulates glucose oxidation and glycogen synthesis in the liver with no or slow toxicity in both normal and diabetic patients [12].

Vanadium is essential for several species of green algae (*Scenedesmus obliquus*, *Chlorella pyrenoidasa*), yellow-green algae (*Bumilariopsis filiformia*), and brown algae (*Fucus spiralis*). V-dependent iodoperoxidases in brown seaweed [40] and chloroperoxidase in the fungus *Curvularia inaequalis* [33, 41] have also been isolated and identified. Haloperoxidases, such as thyroid peroxidase, play important roles in higher animals. Diets low in iodine may amplify responses to dietary V [42]. Vanadium haloperoxidases were extracted from different spp. of Laminariaceae family—*Laminaria saccharina*, *Laminaria hyperborea*, and *Laminaria ochroleuca* [43] and are classified into chloro-, bromo-, and iodoperoxidases. Vanadium chloroperoxidases (VCIPOs) have only been detected in terrestrial organisms, whereas bromoperoxidases (BrPO) and iodoperoxidases (IPO) are more dominant in the marine environment. Isoforms of *L. saccharina* exhibit higher IPO and BrPO activities than *L. hyperborea*. Rehder [44] reported that VCIPOs have an antimicrobial effect which is used potentially in endodontics, i.e., in the treatment of dental biofilms produced by bacteria like *Streptococcus mutans* and *Enterococcus faecalis*. Bromoperoxidase produced from marine algae also contribute up to 25% of the atmospheric bromine load while bromomethanes and iodine may lead to atmospheric ozone depletion and indirectly to the oxidative conversion of dimethyl sulfide and nitric oxide in the atmosphere. Recently, molybdenum-free nitrate reductase enzyme has also been isolated from bacteria *Pseudomonas isachenkovii* [45]. Vanadate under aerobic conditions is reduced to vanadyl form by cellular components such as cysteine containing peptides (glutathione), proteins, catechol, ascorbate, NADH, NADPH, and phenolic compounds [46].

The first essentiality of V in animals was reported by Hopkins and Mohr [47] in rats and chicks and is required at very low < 0.1 to 2 ppm [48] for growth in rats. It is considered essential for rats [49] as less than 100 ppb V in rat diet exhibited reduced body growth [50]. V deficiency is also associated with impaired reproduction, altered red blood cell formation, iron metabolism, and changes in blood lipid level in rats besides stunted growth [51]. It was [31, 52] reported that V deprivation in rats affected thyroid peroxidase in response to changing dietary levels of iodine.

For humans, the safe level of V intake is less than 1.8 mg/day [53]. However, the average diet can provide about 6–20 µg of V/day [54]. V salts have therapeutic properties and are recommended as dietary supplements for patients with diabetes, bodybuilders, and athletes in doses of about 60 mg/day by various National Institutes of Health [55]. V is also present in a number of multi-vitamin/mineral dietary supplements for the humans at levels of approximately 0.025 mg/day [56]. V has become a component of a large number of pills and other dietary supplements to enhance strength and treat diabetes due to its action of mimicking insulin in animal

models [57]. Blood hemoglobin [58] is not affected by V deficiency; however, V-deficient diets increase the blood concentration of creatinine, triglycerides, β-lipoprotein, and the activities of enzyme-like glutamyl transferase and citrate acid cycle without altering the amino acid metabolism [59]. No reflection of toxicity after long-term supplementation of V compounds in blood was observed [60]. Keeping in view the presence of V ubiquitously, it is regarded that V could have the following physiological effects:

1. Affects glucose metabolism by acting as an insulin-mimetic agent and influencing GLUT4 translocation [61]
2. Required for osteogenic and osteoblastic activity in both growth and development [62] and bone collagen synthesis [63, 64]
3. Regulates the activity of haloperoxidase in lower forms [65], thyroid-related enzymes iodoperoxidase in higher animals [66]
4. Possess serum lipid lowering ability [67]
5. Acts as a potential antioxidant agent in diabetic conditions [68]
6. Substitutes phosphates within ATP-driven reactions [69] and interacts with Mg ion [70] in different oxidation states
7. A positive relationship with iron metabolism as important for red blood cell formation [71]
8. Plays a biochemical role in the bioavailability of Fe from milk during lactation [72] as it integrates with lactoferrin

Absorption and Metabolism in Biological System

Vanadyl (IV; VO^{2+} , V^{4+}) and vanadate (V; VO_4^{3-} , V^{5+}) are the two most biologically stable states of V. Both the ions exist in the blood but vanadyl form predominates. Ascidiaceans and other aquatic animals (tunicates) accumulate V in special cells known as vanadocytes. V in the blood of these organisms is more than 10 mM, whereas in the large water bodies, it is approximately 35 nM [73]. Tunicate blood cells support the accumulation of V up to million-fold concentration gradients, but since no V granules are observed in the blood cells, as V(III) exists in a reduced form that is incompatible with physiological conditions. This reduction required NADPH in the tunicate. Studies related to V uptake showed that it [74] is primarily transported to the tunicate's blood plasma via the branchial sacs [75] while some absorption also occurs via the gastrointestinal tract (GIT) where they bind to proteins, i.e., vanabins in the cytoplasm [76] which facilitates its transport and accumulation V in the vacuoles. Vanabin protein isolated previously referred to as vanadium-associated proteins (VAPs) [76, 77] are generally of three types. The isolated vanabins include proteins with apparent molecular weights of 12.5, 15, and 16 kDa [78]. Vanadocytes enter the cell cytoplasm, reduced to +4 oxidation state by vanabins and gets

deposited in vacuoles [73, 79]. These bind V(IV) more strongly than V(V) which suggests that reduction does take place before its association with V ion [80].

The gastrointestinal and respiratory tracts are the main routes from which V is absorbed in the blood and transported to the other parts of the body as citrates, lactates, or phosphates [81] in human and animals. However, V is poorly (only about 10%) absorbed from the gastrointestinal tract [82]. Studies indicate that in animals such as sheep, V is absorbed in the upper and lower GIT, 10- and 100-fold respectively greater than those in the blood. However, in NRC [83], it has been documented that V is absorbed only less than 1%. In vitro studies suggest that V in the anionic or vanadate (HVO_4^{2-}) form can enter cells through phosphate or other anion transport systems [84]. Most of the ingested V is transformed into the cationic (vanadyl) form in the stomach before being absorbed in the duodenum through an unknown mechanism [85]. Dermal absorption of sodium metavanadate has also been reported through the skin [86]. Vanadate is absorbed three to five times more effectively than vanadyl [87]. The percent at which ingested V is absorbed is affected by different absorbability rates for vanadate and vanadyl, the effect of other dietary components (chromium, protein, ferrous ion, chloride, and aluminum hydroxide), on the binding and forms of V in the stomach, and the rate at which vanadate is transformed into vanadyl [88].

The level of V in human plasma is 0.42–0.08 $\mu\text{g/L}$ and is excreted primarily in urine at an average concentration of 22 $\mu\text{g/L}$ [89]. The major route of excretion of unabsorbed V is through feces and urine [90]. Due to low GIT absorption, dietary V is predominantly eliminated, unabsorbed via the feces. In both humans and animals, principle route of elimination for absorbed V is via the kidneys and only a minimal amount (< 10%) of absorbed V is excreted in feces. Animal studies indicated that its excretion is relatively rapid and kidney excretes about 40–60% of a dose of V within 1–3 days of absorption. In humans, daily intakes of 12–30 g V, > 5% of V is absorbed and > 0.8 g/L V is excreted in urine [88]. It was reported that effects of V administration persist even after it has been withdrawn for several days [91]. Other alternative routes of V excretion into the gut include salivary excretion or direct transfer across the intestinal wall. The skin is only a minor route of exposure for V [21].

Distribution in Tissues

Vanadium is found in a wide variety of tissues of higher vertebrate animals, including human and is stored under normal conditions at concentrations less than 10 ng/g fresh weight [88]. Principle organs of V retention are the kidneys, liver, testicles, spleen, brain, heart, muscles, and bones. In plant

and animal cells, V ranged between 10 and 20 nmol [92]. In humans, approximately, 50% of V accumulates in the bones, with the remaining part in the kidneys, spleen, liver, blood, adipose tissue, and brain [93]. Bone apparently is a major sink for excessive retained V in the body though the kidneys accumulate a larger portion of V in the body [94]. In animals, normal liver V concentrations for cattle are usually reported as 6–7 mg/kg (wet-mass basis (WM)); sheep 100–220 mg/kg; dogs, 30–50 mg/kg; chickens, 18–38 mg/kg, and ducks 0.7–2 mg/kg, respectively [95]. The bone accumulates twice V than the kidney and ten times than the liver. The evidences of V storage in bone and other structural tissues in animals showed the increase in dietary V concentration from 0, 50, and 200 ppm in sheep, and bone ash V concentration also increased from 0.4 to 1.7 and 3.8 ppm, respectively [96]. Improvement in the rate of bone formation and mineralization, bone crystal length, and cortical bone toughness was found due to V supplementation. It was reported that V complexes enhanced bone formation rate, increased the osteoid volume in diabetic animals, and also reversed the harmful effects of steroidal drugs on skeletal system [97]. Sodium orthovanadate salt improved all the physical and histological abnormalities of the bone such as osteoporosis induced by glucocorticoid in the rat acting as a tyrosine phosphatase inhibitor [98].

Distribution in Biological Fluids

The form of V in biological fluids is dependent on pH, concentration, presence of oxides as well as chelating agents [99]. V ions are conjugated with transferrin and albumin proteins in blood and are rapidly incorporated into tissues. Transferrin binds approximately 90% of the V transported in the plasma. It is not yet established whether vanadyl-transferrin complex can transfer V into cells through the transferrin receptor or whether ferritin is its storage vehicle. Transferrin has an affinity at least 10-fold greater for serum albumin than that for vanadyl cation [99]. However, serum albumin can associate with up to 20 molecules of V(IV) representing a reservoir for readily accessible V [100]. Immunoglobins have little or no affinity for vanadyl cation [101]. Less than 1% of intracellular V exists in free form where it is present as vanadyl, in association with glutathione, catecholamines, or other small peptides; while in the plasma and body fluids, it is usually bound to transferrin and in red cells to hemoglobin. Plasma V concentration is close to its physiological intracellular concentration (about 20 nM) [102], whereas total body pool of V is estimated to be about 100–200 μg [103] in humans. Its level in human blood varies widely, with increasing V levels in whole blood and in serum it ranged between 0.01 and 0.4 mg/L, approx. below 0.1 mg/L [24].

Role of Vanadium in Carbohydrate, Lipid, and Mineral Metabolism

Role of V includes lowering of plasma cholesterol and triglycerides levels, diuretic and anticarcinogenic effect, and contraction of blood vessels and enhancement of oxygen-affinity of hemoglobin and myoglobin [57] and antidiabetic effect. It inhibits or regulates the action of receptors and non-receptor protein tyrosine kinases depending on its oxidation state [104]. It has the ability to influence enzymatic systems, namely, phosphatases, ATPases, peroxidases, ribonucleases, protein kinases, and oxidoreductases [105] and competitively inhibit activities of phosphoryl transferase enzymes in animal body thereby inhibiting $\text{Na}^+ \text{K}^+$ ATPase activities which regulate the Na^+ pump [106] and controlling the tyrosine phosphatase activity [107]. Similarity between orthovanadium and phosphate ions was reported by Crans et al. [108].

Carbohydrate Metabolism

Among the vanadium salts, peroxovanadium (V) complexes were the first group of compounds having higher insulin activity [109]. Inorganic and organic V compounds improved glucose homeostasis in type 1 and type 2 diabetes besides having antioxidant properties in vivo conditions [101, 108, 110]. In presence of insulin, V lowers the glucose levels [111, 112] at therapeutic doses. Vanadium enhanced metabolic effects of insulin in vivo, exception being the effects on amino acid uptake, protein synthesis, and mitogenesis were not reproducible by V compounds as by insulin in diabetic animals [113] showing that only metabolic and not mitogenic effects are enhanced by V. Insulin-mimetic action of V are likely to be mediated via two pathways, i.e., insulin-dependent and independent signaling cascades to maintain homeostasis in the body. Improved insulin sensitivity in muscle cells is due to increased translocation of GLUT4 to the cell surface and not because of alterations in GLUT4 mRNA or protein expression [114]. Similarly, Trevino and co-workers [115] have reported and developed metforminium decavanadate (MetfDeca), a hypoglycemic and hypolipidemic compound by experimentation on male wistar rats with type 1 and type 2 diabetes mellitus. This has proven to provide protection on pancreatic beta cells of DM1 rats, thereby suggesting a possible regeneration of these cells by recovering their insulin levels. Therefore, MetfDeca could be considered not only as an insulin-mimetic but also as an insulin-enhancing agent. But the mechanism of action is still not clear. Similarly, a new insulin-mimetic compound hexaquis (benzylammonium) decavanadate [116] in rodent adipocytes has been reported to trigger downstream of insulin signals via insulin receptor and phosphatase inhibition, thus activating glucose transport in the complete absence of insulin [117, 118]. B6V10 [(C7H10N)6V10O28.2H2O] is a salt conjugate of

benzylamine and decavanate which acts as a substrate for vascular adhesion protein-1 (SSAO/VAP-1)/semicarbazide-sensitive amine oxidase [119]. This enzyme inhibits B6V10 and prevents lipolysis, thus leads to synergism between benzylamine and vanadate.

Lipid Metabolism

Vanadium compounds modulate several key regulators of lipid metabolism by improving the expression of peroxisome proliferator-activated receptor γ (PPAR γ) and the activation of AMP-activated protein kinase (AMPK) [120, 121]. Expression of adiponectin and its multimerization are also influenced by V [122], thereby inhibiting the activity of PTP1B involved as a crosslink between signal transductions, PPAR γ , and adiponectin regulation, besides cooperating in insulin enhancement [123]. Several altered gene expressions involved in lipid metabolism, oxidative stress, muscle dynamics, protein breakdown and biosynthesis, the complement system, and signal transduction are also corrected by various V compounds [110, 124]. In addition, V compounds also contribute in reducing plasma triglycerides and thus preventing the development of hypertension and coronary heart disease [125]. In the STZ (streptozotocin)-induced diabetic rats, administration of both V and insulin improved lipid metabolism as monitored by plasma levels of total lipid, triglyceride, and lipogenic enzymes [126].

Mineral Metabolism

In rats, [127] insulin along with five vanadium organic complexes, on the status of minerals such as V, Fe, Cu, Zn, Mn, Ca, and K in STZ-diabetic rat tissues, was studied. It was observed that tissue V concentration increased in vanadium-treated rats. The most pronounced influence of vanadium was observed on iron concentration in the spleen with decrease in iron concentration in the spleen while other minerals were not affected.

Vanadium influences iodine metabolism directly by affecting the thyroid gland. Role of vanadium on the iodine level was observed [31] in studies of effect of iodine to V deprivation in rats. Male weanling Wistar-Kyoto rats were supplemented with V at 0 or 1 $\mu\text{g/g}$ and iodine at 0, 0.33, and 25 $\mu\text{g/g}$, respectively. Its deprivation increased thyroid weight and thyroid weight/body ratio whereas decreased the concentration of vanadium in the liver. Interaction between V and iodine was such that as dietary iodine was increased, plasma glucose increased in the vanadium-deficient rats but decreased in the vanadium-supplemented rats. Also, on increasing dietary iodine, thyroid peroxidase activity was decreased and this decrease was more marked in the V-supplemented than the vanadium-deprived rats indicating that V might have a physiological role in affecting iodine metabolism and thyroid

function. Studies on poultry [128] showed the effect of dietary vanadium on chicks fed on phosphorus-deficient diets where vanadium at 10 or 20 mg/kg in diet significantly reduced mortality rate in the phosphorus-deficient chicks. Inclusion of V in the diet resulted in increased serum phosphorus levels in the phosphorus deficient chicks. The above studies reveal that vanadium interacts with other minerals by affecting their action in the biological system.

Pharmacological Effect

Level of V in the body varies in accordance with the consumption of iron and, thus, the level of hemoglobin in the blood is influenced as V is carried by molecules, such as those that transport iron, i.e., transferrin. It is important to maintain sodium, potassium, water, and salt balance in the body as V is also involved in the cellular mechanism of regulation of sodium pump and in maintaining normal blood pressure, reducing edema, influencing muscle and nerve tissues. V compounds are non-competitive inhibitors of Na^+/K^+ -ATPase and mitochondrial aconitase due to their ability to bind to transport proteins [123, 129, 130]. However, Na^+/K^+ -ATPase in vivo may be resistant to inhibition by vanadate due to the cytoplasmic reduction of vanadate to V(IV) by GSH in the cellular environment and V(IV) is a less potent inhibitor of the Na^+/K^+ -ATPase.

Diabetic patients exhibit both abnormal glucose and lipid metabolism, which can be normalized by treatment with insulin. Studies in the animal model [9, 37] and human [131, 132] revealed that simple V salts and V complexes could also alleviate the abnormal diabetic conditions. Inorganic V compounds have a low rate of absorption compared to organic V compounds. Bis(maltolato)oxovanadium(IV) (BMOV) and bis(ethylmaltolato) oxovanadium (IV) (BEOV) are two vanadyl complexes with the $\text{VO}(\text{O}_4)$ coordination mode, which are potent glucose-lowering agents [133] as these organic compounds possess greater potency, lower toxicity, and improved tolerance ability [134].

Earlier findings suggested that V substitutes insulin in the biological system, but later it was reported that it enhances insulin action rather than replacing insulin. V ameliorates hyperlipidemia and hypertension and as counter ions for RNA, DNA, and protein in cell organelles [135] and also used in the treatment of cardiac and neuronal disorders, malignant tumors, viral, parasitic, bacterial infections (such as influenza, HIV, tuberculosis, Chagas' disease, leishmaniasis, and amoebiasis). V compounds are of concern because of its relation with the phosphate ion, its direct interaction with DNA, and its role in balancing reactive oxygen species at the tissue level. However, its role as a medicinal supplement has not been approved.

Insulin-Mimetic Effect

The insulinotropic abilities of V salts have been pointed out in both animal and human studies. In 1899, V and its compounds were first reported as an antidiabetic agent in hyperglycemia, when dietary sodium orthovanadate (Na_3VO_4) reduced glycosuria in human suffering from diabetes [136]. Chronic V treatment reduced insulin requirements without affecting the plasma levels of C peptide, secreted along with insulin in equimolar concentration from pancreatic B cells, in human patients suffering from type 1 diabetes [137]. Studies on V-treated STZ-diabetic rats showed reduced insulin requirements [138]. Thus, evidence from both human and animal studies indicated the improved metabolic condition and decreased insulin requirements in diabetes.

Vanadium salts have the ability to improve insulin sensitivity in type 2 diabetes which is mainly mediated by enhancing peripheral glucose uptake thereby suppressing hepatic glucose output. In obese and type 2 diabetes mellitus rats, V improved glucose metabolism by restoring normal hepatic and skeletal muscle insulin sensitivity. In the liver, V compounds have been reported to inhibit lipogenesis [139] and gluconeogenesis [140], and stimulate glycolysis and glycogen synthesis [141]. In skeletal muscle, V augments glucose uptake [142], primarily by stimulating glycogen formation. This effect of V in restoring normal insulin and glucose levels might be due to competitive inhibition of glucose-6-phosphatase, a key enzyme in the development of insulin resistance and type 2 diabetes [143]. Oral vanadyl sulfate administered for 4 weeks @ 100–150 mg/day reduced fasting glucose in patients with type 2 diabetes [144, 145], whereas fasting glucose and HbA1c continue to reduce for 2 weeks after the end of dietary V in patients with poorly controlled type 2 diabetes [146]. Similar studies on type 2 diabetic patients on dietary sodium metavanadate regime (100 mg/day) for 12 weeks reduced levels of HbA1c, LDL cholesterol, triglycerides, and body mass index (BMI) [102].

Mechanism of Action

Insulin-related studies on V have been mostly carried out on diabetic rats and mice where V supplementation has shown positive effects by normalizing the insulin and plasma glucose levels. In vitro studies related to rats revealed that several inorganic V compounds are similar to insulin in stimulating glucose transport and oxidation in adipocytes, increasing glycogen synthesis in diaphragm and hepatocytes while inhibiting gluconeogenesis in liver cells [147]. The mechanism behind this effect is due to the inhibition of protein tyrosine phosphatases (PTPases) enzyme intracellularly [122, 148] and activation of the insulin receptor (IR). Phosphatases have an affinity for small proteins to large receptors like the phosphorylated insulin receptor. Their mode

of action depends on the substrate and location in the cell. It was reported [149] that the limiting phosphate hydrolysis reactions are either dissociative or an associative mechanisms. PTP1B (protein tyrosine phosphatase 1B) attack the long bonds between the vanadium and oxygen atoms. Vanadium compounds inhibit all phosphatases, including those which are not even mentioned to have associative mechanism. The activation of B subunit of insulin receptor requires increased tyrosine phosphorylation [150] which occurs by preventing the dephosphorylation of the IR or activation of IR protein tyrosine kinase (PTK) which regulates down signaling of proteins for the glucose uptake and transport [130]. Potent non-selective inhibition of PTPases due to V has shown to mimic many of the metabolic actions of insulin both in vivo and in vitro. Metabolic effects of insulin are initiated by activation of its receptor on the surface of the cell leading to the activation of two main signaling cascades referred to as phosphatidylinositol 3-kinase (PI3-K) pathway and mitogen-activated protein kinase (MAPK) pathway. The PI3-K pathway is believed to mediate most of the metabolic effects of insulin, whereas MAPK pathway is mainly involved in mediating the mitogenic effects of insulin [151]. Similar to insulin, V also stimulates both glucose uptake and glycogen synthesis [152, 153]; therefore, insulin receptor and post-receptor sites have been suggested as potential sites for V action. This can be explained further as V compounds generally exert its insulin-enhancing effect through competitive inhibition of regulatory protein phosphatases, mainly protein phosphatase 1B (pp1B) which is the first phosphatase enzyme [78] in the insulin regulatory cascade particularly sensitive to inhibition by V. However, the efficiency of this competitive inhibition depends on the structure of the V complex, the oxidation state of the metal ion, and the nature of the phosphatase [74, 154, 155] thereby differing in orders of magnitude in vivo. As for example, certain V compounds such as peroxovanadate irreversibly oxidize the catalytic cysteine in protein phosphatases [155] while simple vanadate salts [156] do not undergo similar redox chemistry explained by their smaller effect on the autophosphorylation of the IR [157].

The pro-insulin-mimetic action of V involved the suppression of glucose release from the liver and kidney, inhibition of enzyme activities involved in gluconeogenesis, including glucose-6-phosphatase (G-6-Pase), phosphoenolpyruvate carboxykinase (PEPCK), and pyruvate kinase [125] besides insulin-sensitizing effects by stimulating adiponectin through a PKB-dependent transduction pathway [158]. V ions at a cellular level suggest that it behaves as phosphate analogs because of V activating protein tyrosine phosphorylation which in a mechanism similar to insulin solubilize insulin receptor causes its autophosphorylation. The second possible mechanism for its action would be regulation of activity and expression of key intracellular enzymes. Evidence from in vitro studies suggests that vanadium in millimolar

concentrations activates both phosphoinositide 3-kinase and protein kinase (PKB) enzymes. V increases glucose uptake and transports from the intracellular compartment to the cell surface through the insulin-dependent glucose transporter (GLUT4) mechanism regulated by PI3K and B PKB where GLUT4 is translocated to the cell surface membrane.

GLUT4 is the major glucose transporter in muscle that is regulated by insulin. Results from the laboratory have shown that treatment of streptozotocin (STZ)-diabetic rats with BMOV, in the drinking water for 8 weeks enhanced insulin-induced GLUT4 translocation to the plasma membrane in the cardiac muscle [159]. Therefore, suggesting that V might mediate its glucose-lowering effects by enhancing glucose uptake in the insulin-responsive tissues. In vivo studies have shown that V could restore the reduced levels of GLUT4 mRNA and protein expression [160, 161] whereas it might enhance insulin-induced GLUT4 translocation from the intracellular pools to the plasma membrane in the muscle of diabetic animals [159]. But therapeutic doses of V had no effect on PI3-K or PKB activity in the skeletal muscle or liver of diabetic rats suggesting that the effects of V on GLUT4 membrane translocation are likely not mediated through PI3-K or PKB in vivo unlike in vitro conditions. Therefore, it is indicated that insulin-mimetic properties of V ions inhibit glucose release and reduce the activity of glucose-6-phosphatase involved in gluconeogenesis, accelerate transport of glucose and its oxidation, increase glycogen synthesis, attenuate lipogenesis, and inhibit lipolysis.

There are various other mechanisms of insulin-tropic action of V like reduction and increase in the expression of mRNA for neuropeptide Y (NPY) and in the level of leptin in adipose tissue respectively. Another can be the inhibition of tyrosine phosphatase receptor type 1 activity (PTP1B) that result in a loss of appetite and reduction of body weight in animal studies [4, 162, 163]. NPY was inhibited by insulin which regulates appetite and food intake.

In addition to the above, during insulin resistance in animal models, V has the ability to restore the activities of key enzymes in glycogen metabolism (glycogen synthase and phosphorylase a) and other lipogenic enzymes (malic enzyme and glucose 6-phosphate dehydrogenase) [164, 165].

Growth Promoting Effects

Vanadium affects osteogenic and osteoblastic activity at different pharmacological doses by incorporating into hydroxyapatite lattice as it shares similar characters with phosphate ion. The compounds like oxovanadium interact with collagen and bind with the carboxylate group and glycosidic oxygen of the D-glucuronate moieties to help in cell proliferation, differentiation, and mineralization [166]. Yamaguchi et al. [167] reported that serum Ca level increased with increase in the dietary V level (15 and 20 $\mu\text{mol V}/100 \text{ g}$) when dietary V

@ dose rate of 1.0–20.0 $\mu\text{mol V}/100\text{ g}$ body weight as vanadium pentoxide in weanling rats. Vanadium affects mineralization in bones along with DNA content. It was reported that bone calcium content was not altered although bone DNA content and bone alkaline phosphatase (BALP) activity was increased significantly by the dose of 1.0–10.0 $\mu\text{mol V}/100\text{ g}$. A similar study also suggested that simultaneous injection of Zn as zinc sulfate (15.3 $\mu\text{mol Zn}/100\text{ g}$) for 3 days produced an appreciable increase in bone alkaline phosphatase activity, DNA, and calcium content without affecting these parameters if V (2.0 and 20.0 $\mu\text{mol V}/100\text{ g}$) was increased simultaneously. This indicates that a comparatively low dose of vanadium may play a nutritional role in the bone formation of weanling rats and that zinc might alleviate the toxic effect of V with higher doses.

Antitumor Effect

Vanadium checks and corrects the division of cells, thereby acting as an antitumor agent. Depending on dose and type of vanadium compound used, both pro and antitumor properties are exhibited [108, 168]. Lower concentration stimulates whereas high concentration inhibits the proliferation of tumor cells [169]. Organic V compounds have less toxicity and greater bioavailability in a biological system. Vanadium induces the pro-tumor intracellular production of free radicals, leading to DNA strand breakage and chromosomal aberrations [130]. Antitumor properties of V may be due to its inhibitory effect on tyrosine phosphatase and activation of tyrosine phosphorylase enzyme [170]. Alternatively, V also inhibits tumor cell proliferation by blocking cell cycles in the G2 or M phase [168, 108]. It inhibits the generation of carcinogen-derived reactive metabolites via different pathways such as stimulating antioxidant and xenobiotic metabolizing enzymes, suppression of tumor cell proliferation, detoxifying and eliminating reactive intermediates causing apoptosis, and restricting the proliferation of neoplastic cells. A non-toxic low dose of V compounds such as $\text{VO}(\text{acac})_2$ (0.15 mmol/kg) is used for obtaining high-resolution images of tumor interior structures [171] pertaining to its prolonged blood half-life and selective leakage from hyperpermeable tumor vasculature.

Although V affects the glucose and lipid metabolism in a diabetic animal or human via its activation of intracellular signaling pathways, it has no effect on GLUT4 expression or membrane translocation in non-diabetic condition [159]. Again, emphasizing that V restores diabetes-induced metabolic disorders but has no effect on normal metabolism.

Role of Vanadium in Immunity and Antioxidant Defense

The effectiveness of V compounds as immunomodulatory agents depends on its physicochemical characteristics in terms

of availability, selectivity, and specificity, followed by controlled clinical trials in both human and animals. Key factors taken into consideration for immune response by V salts include (a) the nature of V itself (inorganic forms at various oxidation states, metal-organic complex species, organometallic forms, etc.), (b) the nature of ligands-substrates bound to V (e.g., peroxido, oxido, and nonperoxido organic chelators of variable O,N-containing tethers), (c) the oxidation state of V (with V(IV) and V(V) representing the well-established physiological forms in biological fluids), (d) the hydrophilicity and hydrophobicity of the ligands-substrates as well as the arising V complex inorganic-organic species, thereby allowing access to specified molecular loci of action, and (e) the binary and ternary complex metal-organic nature of vanadium. Though the need for such approaches requires exemplified and extensive research efforts in future.

Vanadium compounds are known to be involved in immune regulation and could be used as promising metallodrugs towards future immunotherapy. Vanado-drugs have the potential to influence and resensitize the immune microenvironment by interacting with immune system modulators as well as other transcription factors. It affects immune signaling pathways and activating interleukins, including IL-2, IL-4, IL-6, and IL-10 as diagnostic and immunotherapeutic tools in immunopathological disorders. The low dose of V has a positive stimulatory effect on the immune system as in mice and rats [172]. At lower doses, V regulates the immune system of the animal, affecting both humoral and cellular activities. Among all the oxidation states of V, quadrivalent salts are the most stable [173]. It is reported that B cell expands with an increase in immune response due to the proliferation of splenocytes after stimulation by V compounds [174].

B Cell Signaling

V salts stimulate splenocytes and B cells accounting for the increased immune response [27]. It is reported that B cell expands with an increase in immune response due to the proliferation of splenocytes after stimulation by V compounds [175]. IFN- and total IgG were also amplified in splenocytes, which is correlated with the expansion of B cells although the number of CD3^+ , CD4^+ , and CD8^+ cells of splenocytes remains the same. V affects mitogenic responses in lymphocytes by interacting with T and B cells in a distinctly different manner, thus modulating B cell immune response [27]. Studies revealed that not only action and effects of insulin are mimicked by V treatment in diabetic animals but also B cell lesions are partial, prevented, or treated by V salts on dietary administration [42]. Studies revealed that not only action and effects of insulin are mimicked by V treatment in diabetic animals but also B cell lesions are partial, prevented, or treated by V salts on dietary administration [176].

T Cell Signaling

Similarly, V also activates T lymphocytes that play a central role in cell-mediated immunity and are characterized by the presence of a T cell receptor (TCR) on their cell surface [177]. V alters CD4⁺ T helper (Th) cell expression, serving as an important initiator and regulator of cellular and humoral immune responses against infectious microorganisms and other antigens. Like other metals, V has been found to interact pro-oxidatively with cells of the innate immune system, including neutrophils, macrophages, basophils, as well as epithelial cells [178]. The exposure of activated human neutrophils to V (25 μ M) in the +2, +3, and +4, but not the +5, valence states promoted hydroxyl radical formation by these cells [179] due to an interaction of the metal via Fenton reaction. Though this mechanism may be of greater relevance to macrophages as these cells do not possess the enzyme myeloperoxidase thus neutralizing the competition between the metal and the enzyme for H₂O₂ [180]. V might have the function on intestinal mucosal immunity by affecting the pathways that reduced the lymphocyte population or lymphocyte activation. Dietary administration of 5 and 15 mg/kg V as ammonium metavanadate in day-old avian broilers showed no effect on the number of cytokines in the intestinal mucosa [181] whereas mRNA expression of Toll-like receptors such as TLR4 and TLR7 in lymphoid organs was up-regulated with decreased immunity if more than 30 mg V/kg was administered in the diet [110]. Expression of CD3⁺, CD3⁺CD4⁺, and CD3⁺CD8⁺ T cells in both ileac lamina propria lymphocytes (LPLs) and intraepithelial lymphocytes (IELs) were also influenced by vanadium. Enzymes such as kinases, GTPases, and transcription factors [182] result in changes in cell metabolism, gene expression, and cytoskeletal organization which was affected due to V supplement. Furthermore, this V also influences cellular mechanisms such as survival, tolerance, apoptosis, proliferation, and differentiation into antibody-producing cells or memory B cells. V affects the growth and proliferation of microorganisms by inhibiting mevalonate kinase enzyme which might be the possible reason of slowing down the growth of bacteria, especially gram-positive bacteria, as mevalonate kinase is present in their isoprenoid biosynthesis pathway [183], but its impact on higher animals is still a topic to be looked into. T cells are essential for immunity for every aspect of the adaptive immune response, and their signaling is regulated by V due to change in the number of mature cells migrating from the thymus to the spleen which in turn affect secretion of IL-2 and IL-6. Upregulation in the systemic concentrations of inflammation-related cytokines such as IL-6, IL-8, IL-18, TNF- α (tumor necrosis factor alpha), and C-reactive protein (CRP) [168] are the characteristics of inflammatory reactions. The inflammatory cascade is activated by immune cell mediators, transcription factors, and chemokines [184]. In this support, evidence revealed that V could down-

regulate inflammatory reactions both in vitro and in vivo [42]. Hepatoprotective action of V is indicated by the reduced levels of serum creatinine and blood urea nitrogen suggestive of an ameliorative effect of V salts on renal dysfunction [185]. Neuroprotective properties of V [186] was confirmed by the activity of bis (peroxido)vanadium (Bpv), a specific inhibitor of PTEN's phosphatase which significantly increased IL-10 levels and decreased TNF- α concentration in the ischemic boundary zone of the cerebral cortex. Though PTEN mRNA and protein levels were reduced but PI3K, Akt, and p-GSK-3 β protein expression were increased in the ischemic boundary zone of the cerebral cortex on vanadium (III)-(L-cysteine) treatment [42].

Antioxidant System

Vanadium contributes to antioxidant system improving the oxidative status and reducing free radicals by scavenging superoxide anion, hydroxyl radical, and intracellular reactive oxygen species via inhibition of lipid peroxidation. Thus, it has the potential of restoring the imbalances in the antioxidant system and plasma enzymes which are responsible for the cell dysfunction and destruction. Benefits to scavenge free radicals suggest its ameliorative potential against oxidative stress as it efficiently increases cellular GSH level and also up-regulates mRNA and protein expression of a catalytic subunit of glutamate cysteine ligase (GCLC), which is involved in glutathione (GSH) synthesis [187]. Vanadyl sulfate given @ 100 mg/kg body weight for 60 days in male albino rats reduced the elevated activities of GR, GPx, and GST in the diabetic group [188] and increased plasma GSH levels in obese rats [69]. Lower doses of V complex increased the activity of glutathione peroxidase thus alleviated the effect of reactive oxygen species in the diabetic animals. This improvement in GPx activity might be the action of V in increasing the nuclear translocation and accumulation of phosphorylated Nrf2 which led to amplifying in expression and activity of glutathione peroxidase as reported in human liver cells in vitro [187]. Supplementation of vanadyl sulfate (0.2 mg/ml in drinking water for 7 days) protected diabetic rats from lipid peroxidation as TBARS (thiobarbituric acid reactive species) were also influenced on supplementation of vanadyl sulfate [175].

Oxidative stress in diabetes is involved in both the origin of the disease and increasing secondary complications [189] resulting in the production of free radicals, especially in the pancreas, which is a major cause in the development of insulin resistance in both type 1 [190] and type 2 diabetics [56]. Beneficial or toxic effects of V, in case of insulin sensitivity, are based on its redox regulation in vivo. V corrects and improves glutathione peroxidase, catalase, and superoxide dismutase levels to near normal values in stress conditions such as diabetes. This property of V is supported by findings in the obese rats where oxidative stress was potentially reduced on

dietary supplementation [191] and is known to decrease oxidative damage remarkably in the diabetic heart [192, 193] in rats. Unlike insulin, V is only partially able to control the impaired antioxidation system of diabetic rats.

Toxicity of Vanadium

Despite positive effects of vanadium on various mechanisms, its too high concentration in an organism can disrupt the main functions of the organs. The dose of V is important as it differentiates between a remedy and poison. Generally, V toxicity occurred via two distinct pathways; one is dependent and the other is independent of H₂O₂ production, which could be blocked by either catalase or glutathione peroxidase [194]. Studies on rats depicted no toxic effects at therapeutic doses of V [195]. However, at higher doses, toxicity was observed due to the inhibition of oxidative phosphorylation [89]. Toxicity of V in animals depends on various factors, such as the type of compounds, the degree of oxidation, dose and time of administration [103], which rises with increasing oxidation state; hence, +5 oxidation state of vanadium is the most toxic [89]. Organic V compounds are safer to use in animals [126] than inorganic salts. Signs of V poisoning in humans are heart palpitations, exhaustion, depression, trembling fingers, and hands, affecting respiratory and digestive system with a characteristic green tongue [196]. It was reported that acute systemic toxicity of V impaired oxidative metabolism with suppression of enzymes and respiratory processes in cells and pathological changes within the kidneys, such as degeneration of the renal tubules, congestion in the liver, and inflammation in the intestinal cells [196]. It has been reported that high doses of V can be teratogenic and can lead to lipid peroxidation [197, 198]. Gastrointestinal symptoms, including diarrhea, vomiting leading to dehydration, and weight reduction [199] in humans have also been observed. Other examples showed that salts of V, including, vanadium chloride, vanadyl sulfate, and meta- and orthovanadate (9.2 mg/kg of vanadium for each compound) significantly reduced the number of red blood cells (RBC) in humans inducing peroxidative changes and deformity in erythrocyte membranes, resulting in hemolysis and shortened RBC survival when administered in high doses [200, 201].

Genotoxicity by V compounds has been mainly exhibited in the +4 and +5 oxidation states, resulting in an occurrence of chromosomal aberrations, DNA strand breakage, and hydroxylation of guanosine thereby, causing the generation of free radical production [202, 203]. Mitochondrial functions were mostly affected by V compounds where oxidative stress induced in mitochondria caused PTP opening, leading to the collapse of mitochondrial transmembrane potential (DW_m) and cytochrome c (Cyt c) release initiating cell apoptosis as observed in rat livers [110]. Although in animal studies, decavanadate was found to be a more potent mitochondrial

depolarizing agent and a more potent inhibitor of mitochondrial oxygen consumption than monomeric vanadate [204].

Conclusions

The omnipresence of vanadium in feeds and drinking water and similarity with phosphate and magnesium ions suggest that V also attains a general role in life by influencing on metabolic processes. Functional V compounds have been found important in lower forms of life as V nitrogenases and vanadate-dependent haloperoxidases. It has potential for improving type 1 and 2 diabetic conditions in humans and acts as an antitumor agent and has positive effects on T cells and B cells activity. However, the safe dose of vanadium is still a controversial and the too high concentration of the mentioned element can lead to many various pathological alterations within the organism as it can affect the activities of intracellular enzyme systems and modify physiological processes like digestion, respiration, etc.

References

1. Malhotra VK (1998) Biochemistry for students. New Delhi
2. Eruvbetine D (2003) Canine nutrition and health. A paper presented at the seminar organized by Kensington Pharmaceuticals Nig. Ltd., Lagos
3. Murray RK, Granner DK, Mayes PA, Rodwell VW (2000) Harper's biochemistry. McGraw-Hill, Health Profession Division
4. Underwood EJ, Suttle NF (2010) The mineral nutrition of livestock. CABI, New York
5. Nielsen FH (1998) Ultratrace elements in nutrition: current knowledge and speculation. *J Trace Elem Exp Med* 11:2. [https://doi.org/10.1002/\(SICI\)1520-670X\(1998\)11:2/3<251::AID-JTRA15>3.0.CO;2-Q](https://doi.org/10.1002/(SICI)1520-670X(1998)11:2/3<251::AID-JTRA15>3.0.CO;2-Q)
6. Verma S, Cam MC, McNeil JH (1998) Nutritional factors that can favorably influence the glucose/insulin system: vanadium. *J Am Coll Nutr* 17(1):11–18. <https://doi.org/10.1080/07315724.1998.10718730>
7. Moskalyk RR, Alfanti AM (2003) Processing of vanadium: a review. *Miner Eng* 16(9):793–805. [https://doi.org/10.1016/S0892-6875\(03\)00213-9](https://doi.org/10.1016/S0892-6875(03)00213-9)
8. Baroch F (2006) Vanadium and vanadium alloys. In: Kirk-Othmer Encyclopedia of Chemical Technology. Wiley, New York, pp 1–18. <https://doi.org/10.1002/0471238961.22011401.a01.pub2>
9. Reul Beaneadicté A, Amin SS, Buchet J-P, Ongemba LN, Crans DC, Brichard SM (1999) Effects of vanadium complexes with organic ligands on glucose metabolism: a comparison study in diabetic rats. *Br J Pharmacol* 126:467–477. <https://doi.org/10.1038/sj.bjp.0702311>
10. Mukherjee B, Patra B, Mahapatra S, Banerjee P, Tiwari A, Chatterjee M (2004) Vanadium an element of atypical biological significance. *Toxicol Lett* 150:135–143. <https://doi.org/10.1016/j.toxlet.2004.01.009>
11. Badmaev V, Prakash S, Majeed M (1999) Vanadium: a review of its potential role in the fight against diabetes. *J Altern Complement Med* 5:273–291. <https://doi.org/10.1089/acm.1999.5.273>

12. Harland BF, Harland Williams BA (1994) Is vanadium of human nutritional importance yet? *J Am Diet Assoc* 94(8):891–894. [https://doi.org/10.1016/0002-8223\(94\)92371-X](https://doi.org/10.1016/0002-8223(94)92371-X)
13. Lide DR (2008) *Handbook of chemistry and physics*. CRC Press, Boca Raton
14. NRC (2005) *Mineral tolerances of animals*. National Academy of Sciences, Washington, DC
15. Martin HW, Young TR, Kaplan DI, Simon L, Adriano DC (1996) Evaluation of three herbaceous index plant species for bioavailability of soil cadmium, chromium, nickel and vanadium. *Plant Soil* 182(2):199–207. <https://doi.org/10.1007/BF00029051>
16. Vwioko D, Anoliefo G, Fashemi S (2006) Metal concentration in plant tissues of *Ricinus communis* L.(castor oil) grown in soil contaminated with spent lubricating oil. *J Appl Sci Environ Manag* (3):10, 127–134. <https://doi.org/10.4314/jasem.v10i3.17331>
17. Barker AV, Pilbeam DJ (2015) *Handbook of plant nutrition*. Boca Raton, London
18. Wang JF, Liu Z (1999) Effect of vanadium on the growth of soybean seedlings. *Plant Soil* 2016(1):47–51. <https://doi.org/10.1023/A:1004723509113>
19. EPA (2003) U.S. Environmental Protection Agency. EPA's report on the environment (2003 draft). U.S. Environmental Protection Agency, Washington, DC
20. Anke M (2004) Vanadium—an element both essential and toxic to plants, animals and humans. *Anal Real Acad Nac Farm* 70:961–999
21. Barceloux DG (1999) Vanadium. *J Toxicol Clin Toxicol* 37(2): 265–278
22. NRC (1980) Mineral tolerance of domestic animals. In: *Vanadium*. National Academy Press, Washington, D.C., pp. 534–552
23. Myron DR, Givand SH, Nielsen FH (1977) Vanadium content of selected foods as determined by flameless atomic absorption spectroscopy. *J Agric Food Chem* 25:297–300. <https://doi.org/10.1021/jf60210a036>
24. EFSA (2010) Technical report on selected trace and ultratrace elements: biological role, content in feed and requirements in animal nutrition—elements for risk assessment
25. Berry RE, Armstrong EM, Beddoes RL, Collison D, Ertok SN, Helliwell M, Garner CD (1999) The structural characterization of amavidin. *Angew Chem Int Ed* 38(6):795–797. [https://doi.org/10.1002/\(SICI\)1521-3773\(19990315\)38:6<795::AID-ANIE795>3.0.CO;2-7](https://doi.org/10.1002/(SICI)1521-3773(19990315)38:6<795::AID-ANIE795>3.0.CO;2-7)
26. Hubregtse T, Neeleman E, Maschmeyer T, Sheldon RA, Hanefeld U, Arends JWCE (2005) The first enantioselective synthesis of the amavidin ligand and its complexation to vanadium. *J Inorg Biochem* 99(5):1264–1267. <https://doi.org/10.1016/j.jinorgbio.2005.02.004>
27. Waters MD (1977) Toxicology of vanadium. In: Goyer RA, Mehlman MA (eds) *Advances in modern toxicology. Toxicology of trace elements*, Wiley, New York, pp 147–189
28. WHO (World Health Organization) (2001) Vanadium pentoxide and other inorganic vanadium compounds. *Concise International Chemical Assessment Document 29*. Geneva: WHO. <http://www.inchem.org/documents/cicads/cicads/cicad29.htm>. Accessed April 22, 2005
29. US Department of Energy (1999) Final site observational work plan for the UMTRA project old rifle site GJO–99–88–TAR. U.S. Department of Energy, Grand Junction
30. WHO (World Health Organization) (1988) Vanadium. In: *Environmental Health Criteria* 81. Geneva, pp 1–170
31. Nielson FH, Uthus EO (1990) Vanadium in biological systems. In: Chasteen ND (ed) *Physiology and biochemistry*. Kluwer Academic, London, pp 51–56
32. Clark TA, Deniset JF, Heyliger CE, Pierce GN (2013) Alternative therapies for diabetes and its cardiac complications: role of vanadium. *Heart Fail Rev*. <https://doi.org/10.1007/s10741-013-9380-0>
33. Vilter H (1984) Peroxidases from Phaeophyceae: vanadium (V)-dependent peroxidase from *Asocphyllum nodosum*. *Phytochemistry* 23: 1387–1390. [https://doi.org/10.1016/S0031-9422\(00\)80471-9](https://doi.org/10.1016/S0031-9422(00)80471-9)
34. Cusi K, Cukier S, Defronzo RA, Torres M, Puchulu FM, Redondo JC (2001) Vanadyl sulfate improves hepatic and muscle insulin sensitivity in type 2 diabetes. *J Clin Endocrinol Metab* 86:1410–1417
35. Guo J, Han C, Liu Y (2010) A contemporary treatment approach to both diabetes and depression by cordyceps sinensis, rich in vanadium. *Evid Based Complement Alternat Med* 7(3):387–389. <https://doi.org/10.1210/jcem.86.3.7337>
36. Samanta S, Swamy V, Suresh D, Rajkumar M, Rana B, Rana A, Chatterjee M (2008) Protective effects of vanadium against DMH-induced genotoxicity and carcinogenesis in rat colon: removal of O (6)-methylguanine DNA adducts, p53 expression, inducible nitric oxide synthase downregulation and apoptotic induction. *Mutat Res* 650(2):123–131. <https://doi.org/10.1016/j.mrgentox.2007.11.001>
37. Crans DC, Mahroof-Tahir M, Johnson MD, Wilkins PC, Yang L, Robbins K, Johnson A, Alfano JA, Godzala ME (2003) Vanadium (IV) and vanadium (V) complexes of dipicolinic acid and derivatives. Synthesis, X-ray structure, solution state properties and effects in rats with STZ-induced diabetes. *Inorg Chim Acta* 356: 365–378. [https://doi.org/10.1016/S0020-1693\(03\)00430-4](https://doi.org/10.1016/S0020-1693(03)00430-4)
38. Kreider RB (1999) Dietary supplements and the promotion of muscle growth with resistance exercise. *Sports Med* 27(2):97–110. <https://doi.org/10.2165/00007256-199927020-00003>
39. Aureliano M, Ohlin CA (2014) Decavanadate in vitro and in vivo effects: facts and opinions. *J Inorg Biochem* 137:123–130. <https://doi.org/10.1016/j.jinorgbio>
40. Arnon DL, Wessel G (1953) Vanadium as an essential for green plants. *Nature* 172:1039–1040. <https://doi.org/10.1038/1721039a0>
41. De Boer E, Van Kooyk Y, Tromp MGM, Plat H, Wever R (1986) Bromoperoxidase from *Ascophyllum nodosum*: a novel class of enzymes containing vanadium as prosthetic group. *Biochem Biophys Acta* 869:48–53. [https://doi.org/10.1016/0167-4838\(86\)90308-0](https://doi.org/10.1016/0167-4838(86)90308-0)
42. Nielsen FH (1996) How should dietary guidance be given for mineral elements with beneficial actions or suspect of being essential? *J Nutr* 126:2377S–2385S
43. Almeida M, Filipe S, Humanes M, Maia MF, Melo R, Severino N, da Silva JAL, Fraústo da Silva JJR, Wever R (2001) Vanadium haloperoxidases from brown algae of the Laminariaceae family. *Phytochemistry* 57:633–642. [https://doi.org/10.1016/S0031-9422\(01\)00094-2](https://doi.org/10.1016/S0031-9422(01)00094-2)
44. Rehder D (2014) Vanadium. Its role for humans. In: Sigel A, Sigel H, Sigel RKO (eds) *Interrelations between essential metal ions and human diseases. Metal ions in life sciences*. Springer, pp 139–169. https://doi.org/10.1007/978-94-007-7500-8_5
45. Antipov AN, Dimitry YS, Nikolay PL, Kuenen JG (2003) New enzyme belonging to the family of molybdenum-free nitrate reductases. *Biochem J* 369(1):185–189. <https://doi.org/10.1042/bj20021193>
46. Krosniak M, Francik R, Kołodziejczyk K, Wojtanowska-Krosniak A, Tedeschi C, Petrone V, Grybos R (2014) Investigation of the influence of vanadium compounds treatment in NZO mice model—preliminary study. *Acta Pol Pharm* 71(2):271–278
47. Hopkins LL Jr, Mohr HE (1971) The biological essentiality of vanadium. In: *Newer trace elements in nutrition*. Marcel, New York, pp 195–213

48. Hays VW, Swenson MJ (1985) Minerals and bones. In: Dukes' physiology of domestic animals, 10th edn. Cornell University Press, Ithaca, pp 449–466
49. Kordowiak AM, Holko P (2009) Pochodne wanadu jako zwiaki o istotnym znaczeniu biologicznym. Czesc I. Dzialanie przeciwcukrzycowe. *Post Biol Kom* 36:361–376 (in Polish)
50. Strasia CA (1971) Vanadium: essentiality and toxicity in the laboratory rat. Dissertation. University of California
51. Gruzewska K, Michno A, Pawelczyk T, Bielarczyk A (2014) Essentiality and toxicity of vanadium supplements in health and pathology. *J Physiol Pharmacol* 65(5):603–611
52. Uthus EO, Nielsen FH (1990) Main content area effect of vanadium, iodine and their interaction on growth, blood variables, liver trace elements and thyroid status indices in rats. *Magnes Trace Elem* 9(4):219–226
53. Shepherd LC, Lima H, Ott M (2015) The effects of diet and vanadyl sulfate supplementation on blood glucose levels of diabetics: review of current human data and recommendations for further study. 2(3):00026. <https://doi.org/10.15406/mojph.2015.02.00026>
54. Ulbricht C, Chao W, Costa D, Culwell S, Eichelsdoerfer P (2012) An evidence-based systematic review of vanadium by the natural standard research collaboration. *J Diet Suppl* 9(3):223–251. <https://doi.org/10.3109/19390211.2012.709365>
55. Ivancsits S, Pilger A, Diem E, Schaffer A, Rudiger HW (2002) Vanadate induces DNA strand breaks in cultured human fibroblasts at doses relevant to occupational exposure. *MutatRes* 519: 25–35. [https://doi.org/10.1016/S1383-5718\(02\)00138-9](https://doi.org/10.1016/S1383-5718(02)00138-9)
56. Robertson RP, Harmon J, Tran PO, Tanaka Y, Takahashi H (2003) Glucose toxicity in β -cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. *Diabetes* 52(3):581–587. <https://doi.org/10.2337/diabetes.52.3.581>
57. Poucheret P, Verma S, Grynepas MD, McNeill JH (1998) Vanadium and diabetes. *Mol Cell Biochem* 188(1):73–80. <https://doi.org/10.1023/A:1006820522587>
58. Dai S, Vera E, McNeill JH (1995) Lack of hematological effect of oral vanadium treatment in rats. *Pharmacol Toxicol* 76:263–264. <https://doi.org/10.1023/A:1006820522587>
59. Anke M, Groppel B, Gruhn K, Kosla T, Szilagyi M (1986b) New research on vanadium deficiency in ruminants. In: Proceedings 5th Spurenelement Symposium. University Jena, Germany, Jena, pp 1266–1275
60. Fawcett JP, Farquhar SJ, Thou T, Shand BI (1997) Oral vanadyl sulphate does not affect blood cells, viscosity or biochemistry in humans. *Pharmacol Toxicol* 80:202–206. <https://doi.org/10.1111/j.1600-0773.1997.tb00397.x>
61. Miranda CT, Carvalho S, Yamaki RT, Paniago EB, Borges RH, De Bellis VM (2010) Formation and structure in aqueous solution of complexes between vanadium (V) and aminohydroxamic acids that potentiates vanadium's insulinomimetic activity: l-glutamic γ -hydroxamic and l-aspartic- β -hydroxamic acids. *Inorganica Chimica Acta* 363(14):3776–3783. <https://doi.org/10.1016/j.ica.2010.05.033>
62. Tiago DM, Cancela ML, Aureliano M, Laize V (2008) Vanadate proliferative and anti-mineralogenic effects are mediated by MAPK and PI-3K/Ras/Erk pathways in a fish chondrocyte cell line. *FEBS Lett* 582:1381–1385. <https://doi.org/10.1016/j.febslet.2008.03.025>
63. Sakurai H (2010) Overview and frontier for the development of metallopharmaceuticals. *J Health Sci* 56(2):129–143
64. Dermience M, Lognay G, Mathieu F, Goyens P (2015) Effects of thirty elements on bone metabolism. *J Trace Elem Med Biol* 32: 86–106. <https://doi.org/10.1016/j.jtemb.2015.06.005>
65. Wever R, Hemrika W (2001) Handbook of metalloproteins edited by Albrecht Messerschmidt, Robert Huber, Thomas Poulos and Karl Wieghardt. John Wiley and Sons, Ltd., Chichester
66. Chasteen ND (1990) Vanadium in biological systems—physiology and biochemistry. Kluwer Academic Publishers, Dordrecht
67. Zhang Y, Zhang Q, Feng C, Ren X, Li H, He K, Wang F, Zhou D, Lan Y (2014) Influence of vanadium on serum lipid and lipoprotein profiles: a population-based study among vanadium exposed workers. *Lipids Health Dis* 13:39. <https://doi.org/10.1186/1476-511X-13-39>
68. Kurt O, Ozden T, Ozsoy N, Tunalı S, Can A, Akev N, Yanardag R (2011) Influence of vanadium supplementation on oxidative stress factors in the muscle of STZ-diabetic rats. *BioMetals* 24(5):943–949. <https://doi.org/10.1007/s10534-011-9452-3>
69. Francik R, Krosniak M, Barlik M, Kudła A, Grybos R, Librowski T (2011) Impact of vanadium complexes treatment on the oxidative stress factors in Wistar rats Plasma. *Bioinorgan Chem Appl* 2011:8. <https://doi.org/10.1155/2011/206316>
70. Scibior A (2016) Vanadium (V) and magnesium (Mg) in vivo interactions: a review. *Chem Biol Interact* 258:21433. <https://doi.org/10.1016/j.cbi.2016.09.007>
71. Levina A, McLeod AI, Pulte A, Aitken JB, Lay PA (2015) Biotransformations of antidiabetic vanadium prodrugs in mammalian cells and cell culture media: a XANES spectroscopic study. *Inorg Chem* 54(14):6707–6718. <https://doi.org/10.1021/ic5028948>
72. Sabbioni E, Rade J (1980) Relationship between iron and vanadium metabolism: the association of vanadium with bovine lactoferrin. *Toxicol Lett* 5(6):381–387. [https://doi.org/10.1016/0378-4274\(80\)90019-3](https://doi.org/10.1016/0378-4274(80)90019-3)
73. Kawakami N, Ueki T, Amata Y, Kanamori K, Matsuo K, Gekko K, Michibata H (2009) A novel vanadium reductase, Vanabin2, forms a possible cascade involved in electron transfer. *Biochim Biophys Acta, Proteins Proteomics* 1794(4):674–679. <https://doi.org/10.1016/j.bbapap.2009.01.007>
74. Denu JM, Kohse DL, Vijayalakshmi J, Saper MA, Dixon JE (1996) Visualization of intermediate and transition-state structures in protein-tyrosine phosphatase catalysis. *Proc Natl Acad Sci* 93(6):2493–2498
75. Anderson DH, Berg JR, Swinehart JH (1991) Uptake of vanadium by the ascidian *Ascidia ceratodes*. *Comp Biochem Physiol* 99(1–2):151–158. [https://doi.org/10.1016/0300-9629\(91\)90250-G](https://doi.org/10.1016/0300-9629(91)90250-G)
76. Ueki T, Adachi T, Kawano S, Aoshima M, Yamaguchi N, Kanamori K, Michibata H (2003) Vanadium-binding proteins (vanabins) from a vanadium-rich ascidian *Ascidia sydneiensis samea*. *Biochim Biophys Acta* 1626(1–3):43–50. [https://doi.org/10.1016/S0167-4781\(03\)00036-8](https://doi.org/10.1016/S0167-4781(03)00036-8)
77. Kanda T, Nose Y, Wuchiyama J, Uyama T, Moriyama Y, Michibata H (1997) Identification of a vanadium-associated protein from the vanadium-rich ascidian, *Ascidia sydneiensis samea*. *Zool Sci* 14(1):37–42. [https://doi.org/10.1016/S0167-4781\(03\)00036-8](https://doi.org/10.1016/S0167-4781(03)00036-8)
78. Crans DC, Smee JJ, Gaidamauskas E, Yang L (2004) The chemistry and biochemistry of vanadium and the biological activities exerted by vanadium compounds. *Chem Rev* 104(2):849–902. <https://doi.org/10.1021/cr020607t>
79. Kawakami N, Ueki T, Matsuo K, Gekko K, Michibata H (2006) Selective metal binding by Vanabin2 from the vanadium-rich ascidian, *Ascidia sydneiensis samea*. *Biochim Biophys Acta* 1760: 1096–1101. <https://doi.org/10.1016/j.bbagen.2006.03.013>
80. Eady RR (1996) Structureminisign function relationships of alternative nitrogenases. *Chem Rev* 96(7):3013–3030. <https://doi.org/10.1021/cr950057h>
81. Kiss T, Kiss E, Garribba E, Sakurai H (2000) Speciation of insulinmimetic VO (IV)-containing drugs in blood serum. *J Inorg Biochem* 80:65–73. [https://doi.org/10.1016/S0162-0134\(00\)00041-6](https://doi.org/10.1016/S0162-0134(00)00041-6)
82. Nriagu JP (1998) Vanadium in the environment. In: part 2: health effects. New York

83. NRC (1995) Nutrient requirements of laboratory animals. National Academy Press, Washington, D.C
84. Cantley LCJR, Resh MD, Guidotti G (1978) Vanadate inhibits the red cell (Na⁺, K⁺) ATPase from the cytoplasmic side. *Nature* 272: 552–554. <https://doi.org/10.1038/272552a0>
85. Hirano S, Suzuki KT (1996) Exposure metabolism and toxicity for rare earths and related compounds. *Environ Health Perspect* 104: 85–95
86. Venkataraman BV, Sudha S (2005) Vanadium toxicity. *Asian J Exp Sci* 19(2):127–134
87. Parker RD, Sharma RP (1978) Accumulation and depletion of vanadium in selected tissues of rats treated with vanadyl sulfate and sodium orthovanadate. *J Environ Pathol Toxicol* 2(2):235–245
88. Nielsen FH (1995) Vanadium in mammalian physiology and nutrition. In *Metal ions in biological systems. Vanadium and its role in life*, vol 31. Marcel Dekker, New York, pp 543–573
89. Urban J, Antonowicz-Juchniewicz J, Andrzejak R (2001) Wana-dzagrozenia i nadzieje. *Medycyna Praktyczna* 52:125–133
90. Alimonti A, Petrucci F, Krachler M, Bocca B, Caroll S (2000) Reference values for chromium, nickel and vanadium in urine of youngsters from the urban area of Rome. *J Environ Monit* 2:351–354. <https://doi.org/10.1039/b001616k>
91. Cam MC, Li WM, McNeill JH (1997) Partial preservation of pancreatic beta-cells by vanadium. Evidence for long term amelioration of diabetes. *Metabolism* 46(7):769–778. [https://doi.org/10.1016/S0026-0495\(97\)90121-9](https://doi.org/10.1016/S0026-0495(97)90121-9)
92. Brichard SM, Henquin JC (1995) The role of vanadium in the management of diabetes. *Trends Pharmacol Sci* 16:265–269. [https://doi.org/10.1016/S0165-6147\(00\)89043-4](https://doi.org/10.1016/S0165-6147(00)89043-4)
93. Korbecki J, Baranowska-Bosiacka I, Gutowska I, Chlubek D (2012) Biochemical and medical importance of vanadium compounds. *Acta Biochim Pol* 59(2):195–200
94. Hansen TV, Aaseth J, Alexander (1982) The effect of chelating agents on vanadium distribution in the rat body and on uptake by human erythrocytes. *Arch Toxicol* 50 (3): 195–202. <https://doi.org/10.1007/BF00310851>
95. Gummow B, Botha CJ, Noordhuizen JPTM, Heesterbeek JAP (2005) The public health implications of farming cattle in areas with high background concentrations of vanadium. *Prev Vet Med* 72:281–290. <https://doi.org/10.1016/j.prevetmed.2005.07.012>
96. Hansard SL, Ammerman CB, Henry PR (1982) Vanadium metabolism in sheep. II. Effect of dietary vanadium on performance, vanadium excretion and bone deposition in sheep. *J Anim Sci* 55(2):350–356. <https://doi.org/10.2527/jas1982.552350x>
97. Facchini DM, Yuen VG, Battell ML, McNeill JH, Grynypas MD (2006) The effects of vanadium treatment on bone in diabetic and non-diabetic rats. *Bone* 38:368–377. <https://doi.org/10.1016/j.bone.2005.08.015>
98. Hulley PA, Conradie MM, Langeveldt CR, Hough FS (2002) Glucocorticoid-induced osteoporosis in the rat is prevented by the tyrosine phosphatase inhibitor, sodium orthovanadate. *Bone* 31(1):220–229. [https://doi.org/10.1016/S8756-3282\(02\)00807-4](https://doi.org/10.1016/S8756-3282(02)00807-4)
99. Heinemann G, Fichtl B, Mentler M, Vogt W (2002) Binding of vanadate to human albumin in infusion solutions, to proteins in human fresh frozen plasma, and to transferrin. *J Inorg Biochem* 90:38–42. [https://doi.org/10.1016/S0162-0134\(02\)00399-9](https://doi.org/10.1016/S0162-0134(02)00399-9)
100. Purcell M, Neault JF, Malonga H, Arakawa H, Tajmir-Riahi HA (2001) Interaction of human serum albumin with oxovanadium ions studied by FT-IR spectroscopy and gel and capillary electrophoresis. *Can J Chem* 79(10):1415–1421. <https://doi.org/10.1139/v01-162>
101. Willsky GR, Chi LH, Liang Y, Gaile DP, Hu Z, Crans DC (2006) Diabetes-altered gene expression in rat skeletal muscle corrected by oral administration of vanadyl sulphate. *Physiol Genomics* 26: 192–201. <https://doi.org/10.1152/physiolgenomics.00196.2005>
102. Goldwasser I, Qian S, Gershonov E, Fridkin M, Shechter Y (2000) Organic vanadium chelators potentiate vanadium-evoked glucose metabolism in vitro and in vivo: establishing criteria for optimal chelators. *Mol Pharmacol* 58:738–746. <https://doi.org/10.1124/mol.58.4.738>
103. Tang H, Sun Y, Xiu Q, Lu H, Han H (2007) Cyclooxygenase-2 induction requires activation of nuclear factor of activated T-cells in Beas-2B cells after vanadium exposure and plays anti-apoptotic role. *Arch Biochem Biophys* 468:92–99. <https://doi.org/10.1016/j.abb.2007.09.016>
104. Elberg G, Li J, Shechter Y (1994) Vanadium activates or inhibits receptor and non-receptor protein tyrosine kinases in cell-free experiments, depending on its oxidation state. Possible role of endogenous vanadium in controlling cellular protein tyrosine kinase activity. *J Biol Chem* 269(13):9521–9527
105. Bishayee A, Waghay A, Patel MA, Chatterjee M (2010) Vanadium in the detection, prevention and treatment of cancer: the in vivo evidence. *Cancer Lett* 294:1–12. <https://doi.org/10.1016/j.canlet.2010.01.030>
106. Cantley LC Jr, Josephson L, Warner R, Yanagisawa M, Lechene C, Guidotti G (1977) Vanadate is a potent (Na,K)-ATPase inhibitor found in ATP derived from muscle. *J Biol Chem* 252(21): 7421–7423
107. Krejsa CM, Nadler SG, Esseltyn JM, Kavanagh TJ, Ledbetter JA, Schieven GL (1997) Role of oxidative stress in the action of vanadium phosphotyrosine phosphatase inhibitors redox independent activation of NF-kappaB. *J Biol Chem* 272(17):11541–11549. <https://doi.org/10.1074/jbc.272.17.11541>
108. Imtiaz M, Rizwan MS, Xiong S, Li H, Ashraf M, Shahzad SM, Shahzad M, Rizwan M, Tu S (2015) Vanadium, recent advancements and research prospects: a review. *Environ Int* 80:79–88. <https://doi.org/10.1016/j.envint.2015.03.018>
109. Posner BI, Faure R, Burgess JW, Bevan AP, Lachance D, Zhangsun G, Fantus IG, NGG JB, Hall DA, Soo Lum B, Shaver A (1994) Peroxovanadium compounds: a new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics. *J Biol Chem* 269:4596–4604
110. Wei D, Li M, Ding W (2007) Effect of vanadate on gene expression of the insulin signalling pathway in skeletal muscle of streptozotocin-induced diabetic rats. *J Biol Inorg Chem* 12: 1265–1273. <https://doi.org/10.1007/s00775-007-0294-y>
111. Battell ML, Yuen VG, McNeill JH (1992) Treatment of BB rats with vanadyl sulphate. *Pharmacol Commun* 1:291–301
112. Cam MC, Cross GH, Serrano JJ, Lazaro R, McNeill JH (1993) In vivo antidiabetic actions of Naglivan, an organic vanadyl compound in streptozotocin induced diabetes. *Diabetes Res Clin Pract* 20(2):111–121. [https://doi.org/10.1016/0168-8227\(93\)90004-O](https://doi.org/10.1016/0168-8227(93)90004-O)
113. Fantus IG, Tsiani E (1998) Multifunctional actions of vanadium compounds on insulin signalling pathways: evidence for preferential enhancement of metabolic versus mitogenic effects. *Mol Cell Biochem* 182:109–119. <https://doi.org/10.1023/A:1006853426679>
114. Brichard SM, Ongemba LN, Henquin JC (1992) Oral vanadate decreases muscle insulin resistance in obese fa/fa rats. *Diabetologia* 35:522–527. <https://doi.org/10.1007/BF00400479>
115. Trevino S, Velazquez-Vazquez D, Sanchez-Lara E, Diaz-Fonseca A, Flores-Hernandez JA, Perez-Benitez A, Brambila-Colombres E, Gonzalez-Vergara E (2016) Metforminium decavanadate as a potential metallopharmaceutical drug for the treatment of diabetes mellitus. *Oxidative Med Cell Longev*. <https://doi.org/10.1155/2016/6058705>
116. Carpena C, Garcia-Vicente S, Serrano M, Marti L, Belles C, Royo M, Galitzky J, Zorzano A, Testar X (2017) Insulin-mimetic compound hexakis (benzylammonium) decavanadate is antilipolytic in human fat cells. *World J Diabetes* 8(4):143–153. <https://doi.org/10.4239/wjcd.v8.i4.143>

117. Yraola F, García-Vicente S, Marti L, Albericio F, Zorzano A, Royo M (2007) Understanding the mechanism of action of the novel SSAO substrate (C7NH10)6(V10O28).2H2O, a prodrug of peroxovanadate insulin mimetics. *Chem Biol Drug Des* 69:423–428. <https://doi.org/10.1111/j.1747-0285.2007.00516.x>
118. Zorzano A, Palacin M, Marti L, García-Vicente S (2009) Arylalkylamine vanadium salts as new anti-diabetic compounds. *J Inorg Biochem* 103:559–566. <https://doi.org/10.1016/j.jinorgbio.2009.01.015>
119. Yraola F, Zorzano A, Albericio F, Royo M (2009) Structure-activity relationships of SSAO/VAP-1 arylalkylamine-based substrates. *Chem Med Chem* 4:495–503. <https://doi.org/10.1002/cmdc.200800393>
120. Park SJ, Youn C, Hyun JW, You HJ (2013) The anti-obesity effect of natural vanadium-containing Jeju ground water. *Biol Trace Elem Res* 151:294–300. <https://doi.org/10.1007/s12011-012-9557-8>
121. Huang M, Wu Y, Wang N, Wang Z, Zhao P, Yang X (2014) Is the hypoglycemic action of vanadium compounds related to the suppression of feeding? *Biol Trace Elem Res* 157:242–248. <https://doi.org/10.1007/s12011-013-9882-6>
122. Swarup G, Cohen S, Garbers DL (1982) Inhibition of membrane phosphotyrosyl-protein phosphatase activity by vanadate. *Biochem Biophys Res Commun* 107:1104–1109. [https://doi.org/10.1016/0006-291X\(82\)90635-0](https://doi.org/10.1016/0006-291X(82)90635-0)
123. Wu Y, Huang M, Zhao P, Yang X (2013) Vanadyl acetylacetonate upregulates PPAR γ and adiponectin expression in differentiated rat adipocytes. *J Biol Inorg Chem* 18:623–631. <https://doi.org/10.1007/s00775-013-1007-3>
124. Garcia-Vicente S, Yraola F, Marti L (2007) Oral insulinmimetic compounds that act independently of insulin. *Diabetes* 56:486–493. <https://doi.org/10.2337/db06-0269>
125. Fraqueza G, Ohlin CA, Casey WH, Aureliano M (2012) Sarcoplasmic reticulum calcium ATPase interactions with decanionate, decavanadate, vanadate, tungstate and molybdate. *J Inorg Biochem* 107:82–89. <https://doi.org/10.1039/c2dt31688a>
126. Saxena AK, Srivastava P, Kale RK, Baquer NZ (1993) Impaired antioxidant status in diabetic rat liver: effect of vanadate. *Biochem Pharmacol* 45(3):539–542. [https://doi.org/10.1016/0006-2952\(93\)90124-F](https://doi.org/10.1016/0006-2952(93)90124-F)
127. Krosniak M, Kowalska J, Francik R, Gryboś R, Blusz M, Kwiatek WM (2013) Influence of vanadium–organic ligands treatment on selected metal levels in kidneys of STZ rats. *Biol Trace Elem Res* 153(1–3):319–328. <https://doi.org/10.1007/s12011-013-9688-6>
128. Hill CH (1994) Interaction of vanadium and phosphorus in chicks. *Biol Trace Elem Res* 46(3):269–278. <https://doi.org/10.1007/BF02789302>
129. Ukkola O, Santaniemi M (2002) Protein tyrosine phosphatase 1B: a new target for the treatment of obesity and associated co-morbidities. *J Intern Med* 251(6):467–475. <https://doi.org/10.1046/j.1365-2796.2002.00992.x>
130. Srivastava AK, Mehdi MS (2004) Insulino-mimetic and anti-diabetic effects of vanadium compounds diabetes. *Diabet Med* 22:2–13. <https://doi.org/10.1111/j.1464-5491.2004.01381>
131. Goldfine AB, Patti ME, Zuberi L, Goldstein BJ, LeBlanc R, Landaker EJ, Jiang ZY, Willsky GR, Kahn CR (2000) Metabolic effects of vanadyl sulfate in humans with non-insulin-dependent diabetes mellitus: in vivo and in vitro studies. *Metabolism* 49:400–410. [https://doi.org/10.1016/S0026-0495\(00\)90418-9](https://doi.org/10.1016/S0026-0495(00)90418-9)
132. Halberstam M, Cohen N, Shlimovich P, Rossetti L, Shamoon H (1996) Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. *Diabetes* 45(5):659–666. <https://doi.org/10.2337/diab.45.5.659>
133. Marzban L, McNeill JH (2003) Insulin-like actions of vanadium: potential as a therapeutic agent. *J Trace Elem Exp Med* 16:253–267. <https://doi.org/10.1002/jtra.10034>
134. McNeill JH, Yuen VG, Dai S, Orgiv C (1995) Increased potency of vanadium using organic ligands. *Mol Cell Biochem* 153:175–180. <https://doi.org/10.1007/BF01075935>
135. Sigel A, Sigel H, Sigel R (2013) Interrelations between essential metal ions and human diseases, vol 13, Zurich, Switzerland. <https://doi.org/10.1007/978-94-007-7500-8>
136. Gonzalez-Sanchez C, Bermudez-Pena C, Guerrero-Romero F, Trenzado CE, Montes-Bayon M, Sanz-Medel A, Llopis J (2012) Effect of bis(maltolato)oxovanadium (IV) (BMOV) on selenium nutritional status in diabetic streptozotocin rats. *Brit J Nutr* 108:893–899. <https://doi.org/10.1017/S0007114511006131>
137. Goldfine AB, Simonson DC, Folli F, Patti ME, Kahn CR (1995) Metabolic effects of sodium metavanadate in humans with insulin-dependent and noninsulin-dependent diabetes mellitus in vivo and in vitro studies. *J Clin Endocrinol Metab* 80:3311–3320. <https://doi.org/10.1210/jcem.80.11.7593444>
138. Domingo JL, Gomez M (2016) Vanadium compounds for the treatment of human diabetes mellitus: a scientific curiosity? A review of thirty years of research. *Food Chem Toxicol* 95:137–141. <https://doi.org/10.1016/j.fct.2016.07.005>
139. Valera A, Rodriguez-Gil JE, Bosch F (1993) Vanadate treatment restores the expression of genes for key enzymes in the glucose and ketone bodies metabolism in the liver of diabetic rats. *J Clin Invest* 92:4–11. <https://doi.org/10.1172/JCI116580>
140. Brichard SM, Desbuquois B, Girard J (1993) Vanadate treatment of diabetic rats reverses the impaired expression of genes involved in hepatic glucose metabolism. Effects on glycolytic and gluconeogenic enzymes, and on glucose transport GLUT2. *Mol Cell Endocrinol* 91(1–2):91–97. [https://doi.org/10.1016/0303-7207\(93\)90259-M](https://doi.org/10.1016/0303-7207(93)90259-M)
141. Khandelwal RL, Pugazhenth S (1995) In vivo effects of vanadate on hepatic glycogen metabolizing and lipogenic enzymes in insulin-dependent and insulin-resistant diabetic animals. *Mol Cell Biochem* 153:87–94
142. Carey JD, Azevedo JL, Morris PG, Pories WJ, Dohm GL (1995) Okadaic acid, vanadate, and phenylarsine oxide stimulate 2-deoxyglucose transport in insulin-resistant human skeletal muscle. *Diabetes* 44(6):682–688. <https://doi.org/10.1007/BF01075922>
143. Kawabe K, Yoshikawa Y, Adachi Y, Sakurai H (2006) Possible mode of action for insulinomimetic activity of vanadyl(IV) compounds in adipocytes. *Life Sci* 78:2860–2866. <https://doi.org/10.1016/j.lfs.2005.11.008>
144. Yeh GY, Eisenberg DM, Kaptchuk TJ, Phillips RS (2003) Systematic review of herbs and dietary supplements for glycemic control in diabetes. *Diabetes Care* 26:1277–1294
145. Connell B (2001) Select vitamins and minerals in the management of diabetes. *Diabetes Spectrum* 14:133–148. <https://doi.org/10.2337/diaspect.14.3.133>
146. Ingram JL, Antao-Menezes A, Turpin EA (2007) Genomic analysis of human lung fibroblasts exposed to vanadium pentoxide to identify candidate genes for occupational bronchitis. *Respir Res* 8:1–13. <https://doi.org/10.1186/1465-9921-8-34>
147. Tolman EL, Barris E, Burns M, Pansini A, Partridge R (1979) Effects of vanadium on glucose metabolism in vitro. *Life Sci* 25(13):1159–1164. [https://doi.org/10.1016/0024-3205\(79\)90138-3](https://doi.org/10.1016/0024-3205(79)90138-3)
148. Irving E, Stoker AW (2017) Vanadium compounds as PTP inhibitors. *Molecules* 22(12):2269
149. Aureliano M (2014) Decavanadate contribution to vanadium biochemistry: in vitro and in vivo studies. *Inorg Chim Acta* 420:4–7. <https://doi.org/10.1016/j.jinorgbio>
150. White MF (2002) IRS proteins and the common path to diabetes. *Am J Physiol Endocrinol Metab* 283:413–422. <https://doi.org/10.1152/ajpendo.00514.2001>
151. Hei YJ, Farahbakhshian S, Chen X, Battell ML, McNeill JH (1998) Stimulation of MAP kinase and S6 kinase by vanadium

- and selenium in rat adipocytes. *Mol Cell Biochem* 178(1–2):367–375. <https://doi.org/10.1152/ajpendo.00514.2001>
152. Brannick B, Kocak M, Solomon S (2017) Vanadium in glucose metabolism: past, present and future. *J Toxicol Pharmacol* 1:011
 153. Jackson TK, Saffhanick AI, Sparks JD, Sparks CE, Bolognino M, Amatruda JM (1988) Insulin-mimetic effects of vanadate in primary cultures of rat hepatocytes. *Diabetes* 37:1234–1240. [https://doi.org/10.1016/S1383-5718\(02\)00138-9](https://doi.org/10.1016/S1383-5718(02)00138-9)
 154. Cuncic C, Detich N, Ethier D (1999) Vanadate inhibition of protein tyrosine phosphatases in Jurkat cells: modulation by redox state. *J Biol Inorg Chem* 4:354–359. <https://doi.org/10.1007/s007750050322>
 155. Huyer G, Liu S, Kelly J, Moffat J, Payette P, Kennedy B, Tsaprailis G, Gresser MJ, Ramachandran C (1997) Mechanism of inhibition of protein-tyrosine phosphatases by vanadate and pervanadate. *J Biol Chem* 272(2):843–851. <https://doi.org/10.1074/jbc.272.2.843>
 156. Castan I, Wijkander J, Manganiello V, Degerman E (1999) Mechanisms of inhibition of lipolysis by insulin, vanadate and peroxovanadate in rat adipocytes. *Biochem J* 339(2):281–289. <https://doi.org/10.1042/bj3390281>
 157. Fantus IG, Deragon G, Lai R, Tang S (1995) Modulation of insulin action by vanadate: evidence of a role for phosphotyrosine phosphatase activity to alter cellular signalling. *Mol Cell Biochem* 153:103–112. <https://doi.org/10.1007/BF01075924>
 158. Seale AP, de Jesus LA, Park M, Kim YS (2006) Vanadium and insulin increase adiponectin production in 3T3-L1 adipocytes. *Pharmacol Res* 54:30–38. <https://doi.org/10.1016/j.phrs.2006.01.013>
 159. Li SH, McNeill JH (2001) In vivo effects of vanadium on GLUT4 translocation in cardiac tissue of STZ-diabetic rats. *Mol Cell Biochem* 217:121–129. <https://doi.org/10.1023/A:1007224828753>
 160. Kopp SJ, Daar J, Paulson DJ, Romano FD, Laddaga R (1997) Effects of oral vanadyl treatment on diabetes-induced alterations in heart GLUT4 transporter. *J Mol Cell Cardiol* 29:2355–2362. <https://doi.org/10.1006/jmcc.1997.0469>
 161. Mohammad A, Sharma V, McNeill JH (2002) Vanadium increases GLUT4 in diabetic rat skeletal muscle. *Mol Cell Biochem* 233(1–2):139–143. <https://doi.org/10.1023/A:1015558328757>
 162. Rodriguez-Mercado JJ, Roldan-Reyes E, Altamirano-Lozano M (2003) Genotoxic effects of vanadium (IV) in human peripheral blood cells. *Toxicol Lett* 144:359–369. [https://doi.org/10.1016/S0378-4274\(03\)00255-8](https://doi.org/10.1016/S0378-4274(03)00255-8)
 163. Liem DA, Gho CC, Gho BC, Kazim S, Manintveld OC, Verdouw PD, Duncker DJ (2004) The tyrosine phosphatase inhibitor bis(maltolato)-oxovanadium attenuates myocardial reperfusion injury by opening ATP-sensitive potassium channels. *J Pharmacol Exp Ther* 309:1256–1262. <https://doi.org/10.1124/jpet.103.062547>
 164. Pugazhenti S, Angel JF, Khandelwal RL (1993) Effects of high sucrose diet on insulin-like effects of vanadate in diabetic rats. *Mol Cell Biochem* 122(1):77–84. <https://doi.org/10.1007/BF00925740>
 165. Clark AS, Fagan JM, Mitch WE (1985) Selectivity of insulin-like actions of vanadate on glucose and protein metabolism in skeletal muscle. *Biochem J* 232(1):273–276. <https://doi.org/10.1042/bj2320273>
 166. Michibata H, Sakurai H (1990) In: Chasteen ND (ed) Vanadium in biological systems. Kluwer, Boston
 167. Yamaguchi M, Oishi H, Suketa Y (1989) Effect of vanadium on bone metabolism in weanling rats: zinc prevents the toxic effect of vanadium. *Res Exp Med (Berl)* 189(1):47–53
 168. Evangelou AM (2002) Vanadium in cancer treatment. *Crit Rev Oncol Hematol* 42:249–265. [https://doi.org/10.1016/S1040-8428\(01\)00221-9](https://doi.org/10.1016/S1040-8428(01)00221-9)
 169. Dessoize B (2004) Metal and metal compounds in cancer treatment. *Anticancer Res* 24(3a):1529–1544
 170. Holko P, Ligeza J, Kisielewska J, Kordowiak AM, Klein A (2008) The effect of vanadyl sulphate (VOSO₄) on autocrine growth of human epithelial cancer cell lines. *Pol J Pathol* 59(1):3–8
 171. Mustafi D, Peng B, Foxley S, Makinen MW, Karczmar GS, Zamora M, Ejnik J, Martin H (2009) New vanadium-based magnetic resonance imaging probes: clinical potential for early detection of cancer. *J Biol Inorg Chem* 8:1187–1197. <https://doi.org/10.1007/s00775-009-0562-0>
 172. Alexandrova R, Alexandrov I, Nikolova E (2002) Effect of orally administered ammonium vanadate on the immune response of experimental animals. *Comptes Rendus de l' Academie Bulgare des Sciences* 55(3):69
 173. Tsave O, Petanidis S, Kioseoglou E, Yavropoulou MP, Yovos JG, Anastakis D, Tsepa A, Salifoglou A (2016) Role of vanadium in cellular and molecular immunology: association with immune-related inflammation and pharmacotoxicology mechanisms. *Oxid Med Cell Longev*. <https://doi.org/10.1155/2016/4013639>
 174. Ha D, Joo H, Ahn G, Kim MJ, Bing SJ, An S, Kim H, Kang KG, Lim YK, Jee Y (2012) Jeju ground water containing vanadium induced immune activation on splenocytes of low dose 226Ra-irradiated mice. *Food Chem Toxicol* 50(6):2097–2105. <https://doi.org/10.1016/j.fct.2012.03.041>
 175. Harati M, Ani M (2006) Low doses of vanadyl sulfate protect rats from lipid peroxidation and hypertriglyceridemic effects of fructose-enriched diet. *Int J Diab Metabol* 14(3):134–137
 176. Mongold JJ, Cros GH, Vian L, Tep A, Ramanadham S, Siou G, Diaz J, McNeill JH, Serrano JJ (1990) Toxicological aspects of vanadyl sulphate on diabetic rats: effects on vanadium levels and pancreatic B-cell morphology. *Pharmacol Toxicol* 67(3):192–198. <https://doi.org/10.1111/j.1600-0773.1990.tb00812.x>
 177. Malissen B, Gregoire C, Malissen M, Roncagalli R (2014) Integrative biology of T cell activation. *Nat Immunol* 15(9):790–797. <https://doi.org/10.1038/ni.2959>
 178. Theron AJ, Tintinger GR, Anderson R (2012) Harmful interactions of non-essential heavy metals with cells of the innate immune system. *J Clin Toxicol* 3005. <https://doi.org/10.4172/2161-0495.S3-005>
 179. Fickl H, Theron AJ, Grimmer HR, Anderson R (2006) Vanadium promotes hydroxyl radical formation by activated human neutrophils. *Free Radic Biol Med* 40(1):146–155. <https://doi.org/10.4172/2161-0495.S3-005>
 180. Davies MJ (2011) Myeloperoxidase derived oxidation: mechanisms of biological damage and its prevention. *J Clin Biochem Nutr* 48(1):8–19. https://doi.org/10.3164/jcbn.11_006FR
 181. Deng Y, Cui H, Peng X, Fang J, Wang K, Cui W, Liu X (2012) Dietary vanadium induces oxidative stress in the intestine of broilers. *Biol Trace Elem Res* 145(1):52–58. <https://doi.org/10.1007/s12011-011-9163-1>
 182. Van Vleet JF, Boon GD, Ferrans VJ (1981) Induction of lesions of selenium-vitamin E deficiency in weanling swine fed silver, cobalt, tellurium, zinc, cadmium, and vanadium. *Am J Vet Res* 42(5):789–799
 183. Ghrebeblou M, Arjmand G, Haeri MR, Khazeni M (2015) Nonselective mevalonate kinase inhibitor as a novel class of antibacterial agents. *Cholesterol* 2015:147601. <https://doi.org/10.1155/2015/147601>
 184. Muralidharan S, Mandrekar P (2013) Cellular stress response and innate immune signaling: integrating pathways in host defense and inflammation. *J Leukoc Biol* 94(6):1167–1184. <https://doi.org/10.1189/jlb.0313153>
 185. Basu A, Singha S, Roy A, Bhattacharjee A, Bhuniya A, Baral R, Biswas J, Bhattacharya S (2015) Vanadium(III)-L-cysteine protects cisplatin-induced nephropathy through activation of Nrf2/

- HO-1 pathway. *Free Radic Res* 50(1):39–55. <https://doi.org/10.3109/10715762.2015.1102908>
186. Mao LL, Hao DL, Mao XWXYF, Huang TT, Wu BN, Wang LH (2015) Neuroprotective effects of bisperoxovanadium on cerebral ischemia by inflammation inhibition. *Neurosci Lett* 602:120–125. <https://doi.org/10.1016/j.neulet.2015.06.040>
187. Kim AD, Zhang R, Ah Kang K, Jin You H, Won Hyun J (2011) Increased glutathione synthesis following Nrf2 activation by vanadyl sulfate in human Chang liver cells. *Int J Mol Sci* 12: 8878–8894. <https://doi.org/10.3390/ijms12128878>
188. Yilmaz-Ozden T, Sirin OK, Tunali S, Akev N, Can A, Yanardag R (2014) Ameliorative effect of vanadium on oxidative stress in stomach tissue of diabetic rats. *Bosn J Basic Med Sci* 14(2): 105–109
189. Evans JL, Goldfine ID, Maddux BA, Grodsky GM (2003) Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. *Diabetes* 52:599–622. <https://doi.org/10.1210/er.2001-0039>
190. Desco MC, Asensi M, Marquez R, Martinex-Vallas J, Vento M, Pallardo FY, Sastre J, Vina J (2002) Xanthine oxidase is involved in free radical production in type 1 diabetes. *Diabetes* 51(4):1118–1124. <https://doi.org/10.2337/diabetes.51.4.1118>
191. Ozturk N, Olgar Y, Ozdemir S (2013) Trace elements in diabetic cardiomyopathy: an electrophysiological overview. *World J Diabetes* 4:92–100. <https://doi.org/10.4239/wjd.v4.i4.92>
192. Genet G, Kale RK, Baquer NZ (2002) Alterations in antioxidant enzymes and oxidative damage in experimental diabetic rat tissues: effect of vanadate and fenugreek (*Trigonella foenum graecum*). *Mol Cell Biochem* 236(1):7–12. <https://doi.org/10.1023/A:101610313>
193. Bhuiyan MS, Fukunaga K (2009) Cardioprotection by vanadium compounds targeting Akt-mediated signaling. *Aust J Pharm* 110: 1–13. <https://doi.org/10.1254/jphs.09R01CR>
194. Capella MA, Capella LS, Valente RC (2007) Vanadate-induced cell death is dissociated from H₂O₂ generation. *Cell Biol Toxicol* 23:413–420. <https://doi.org/10.1007/s10565-007-9003-4>
195. Srivastava AK, Mehdi MZ (2005) Insulino-mimetic and antidiabetic effects of vanadium compounds. *Diabetes Med* 22:2–13. <https://doi.org/10.1111/j.1464-5491.2004.01381.x>
196. Boulassel B, Sadeg N, Roussel O, Perrin M, Belhadj-Tahar H (2011) Fatal poisoning by vanadium. *Forensic Sci Int* 206:79–81. <https://doi.org/10.1016/j.forsciint.2010.10.027>
197. Aureliano M, Gandara RM (2005) Decavanadate effects in biological systems. *J Inorg Biochem* 99:979–985. <https://doi.org/10.1016/j.forsciint.2010.10.027>
198. Villani P, Cordelli E, Leopardi P, Siniscalchi E, Veschetti E, Fresegna AM, Crebelli R (2007) Evaluation of genotoxicity of oral exposure to tetravalent vanadium in vivo. *Toxicol Lett* 170: 11–18. <https://doi.org/10.1016/j.toxlet.2006.07.343>
199. Smith DM, Pickering RM, Lewwith GT (2008) A systematic review of vanadium oral supplements for glycaemic control in type 2 diabetes mellitus. *Int J Med* 101:351–358. <https://doi.org/10.1093/qjmed/hcn003>
200. Suwalsky M, Fierro P, Villena F (2012) Human erythrocytes and neuroblastoma cells are in vitro affected by sodium orthovanadate. *Biochim Biophys Acta* 1818:2260–2270. <https://doi.org/10.1016/j.bbame.2012.04.012>
201. Suwalsky M, Fierro P, Villena F (2013) Effects of sodium metavanadate on in vitro neuroblastoma and red blood cells. *Arch Biochem Biophys* 535:248–256. <https://doi.org/10.1016/j.abb.2013.04.006>
202. Thompson KH, Lichter J, LeBel C, Scaife MC, McNeill JH, Orvig C (2009) Vanadium treatment of type 2 diabetes—a view to the future. *J Inorg Biochem* 103:554–558. <https://doi.org/10.1016/j.jinorgbio.2008.12.003>
203. Montiel-Davalos A, Gonzalez-Villava A, Rodriguez-Lara V, Montano LF, Fortoul TI, Lopez-Marure R (2012) Vanadium pentoxide induces activation and death of endothelial cells. *J Appl Toxicol* 32(1):26–33. <https://doi.org/10.1002/jat.1695>
204. Soares SS, Gutierrez-Merino C, Aureliano M (2007) Decavanadate induces mitochondrial membrane depolarization and inhibits oxygen consumption. *J Inorg Biochem* 101:789–796. <https://doi.org/10.1016/j.jinorgbio.2007.01.012>